Hypogonadism; Ovarian

3

Review clinical trials related to Hypogonadism; Ovarian. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome

This 5-week, phase IV randomized crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The objective is to establish the equipotency between the two estradiol regimens by evaluating various estradiol-dependent surrogate markers. The study involves 50 women with TS, aged 18-50 years, who are randomized to receive either oral or transdermal ERT for 14 days, followed by a crossover to the alternate treatment for another 14 days, with a one-week washout period in between. Blood tests are conducted at baseline, after the first 14 days of treatment, after the washout period, and after the final 14 days of treatment. The investigators anticipate that this study will provide clinicians with a better understanding of ERT in treating women with TS.

Participants needed: 50
Trial details
Phase: Phase 4Age: 18-50Biological sex: FemaleType: InterventionalSponsor: Aarhus University HospitalUpdated: Aug 23, 2024Locations: 1
Eligibility criteria

Diagnosis of TS regardless of karyotype [+2]

Active systemic chronic diseases [+7]

Status: Recruiting

Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome

This 14-month, phase IV, randomized controlled crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The study's objectives are to clarify endocrine, metabolic, cardiovascular, and thromboembolic risk factors in TS after a wash-out period without estrogen (E2) treatment; compare the effects of oral versus transdermal (TD) ERT regimens; and examine the long-term effects of E2 administration via these two routes. The study involves 50 TS women aged 18-50 years and 50 control participants. TS participants are randomized to receive either oral or TD ERT for six months, followed by crossover to the alternate treatment for another six months. Prior to randomization, any existing ERT will be discontinued for a 1-month washout period. A second 1-month washout period will occur between the two 6-month treatment phases. Laboratory analyses and clinical investigations are performed after the first wash-out period, after the first six months of treatment, and after the last six months of treatment. We anticipate that this study may provide a basis for new and improved recommendations for sex hormone replacement therapy in TS.

Participants needed: 50
Trial details
Phase: Phase 4Age: 18-50Biological sex: FemaleType: InterventionalSponsor: Aarhus University HospitalUpdated: Aug 26, 2024Locations: 1
Eligibility criteria

Diagnosis of TS regardless of karyotype [+8]

Active systemic chronic diseases [+8]

Status: Recruiting

Association Between Human Immunodeficiency Virus (HIV) Infection and Male Hypogonadism

Cross-sectional study investigating the prevalence of hypogonadism in HIV-infected MSM population

Participants needed: 1,200
Trial details
Age: 20+Biological sex: MaleType: ObservationalSponsor: National Taiwan University HospitalUpdated: Mar 3, 2021Locations: 1Duration: 10 Years
Eligibility criteria

HIV-infected men who have sex with men [+1]

Use of testosterone supplement, anabolic steroid in the past one year. [+6]